Vertex Pharma (VRTX) Tops Q3 EPS by 5c; bumps guidance

Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $3.97, $0.05 better than the analyst estimate of $3.92. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.5 billion.

GUIDANCE:

Vertex Pharma sees FY2023 revenue of $9.85 billion, versus prior guidance of $9.7-$9.8 billion and consensus of $9.87 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
• Pfizer reafffirms 2026 guidance after CFO transition announcement